Skip to main content
HRTX
NASDAQ Life Sciences

Heron Posts Q3 Revenue of $35.3M, Down 7.8%, as CorMedix Asset Sale Looms

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
7
Price
$0.379
Mkt Cap
$55.627M
52W Low
$0.261
52W High
$1.575
52W Position info
45% above low
Off High info
76% below high
Rel. Volume info
0.5× avg
Market data snapshot near publication time

HRTX sits 45% above its 52-week low of $0.261.

Summary

Heron reported Q3 2026 net revenue of $35.3 million, down 7.8% year-over-year, with $23.4 million in cash, in the same 8-K cycle as its $145 million cash asset sale to CorMedix.


Key Events · Earnings and Guidance · HRTX

  • Q3 Revenue Falls 7.8%

    Total net revenue was $35.3 million versus $38.2 million in Q3 2025 and $37.7 million in Q2 2026.

  • Acute Care Grows, Oncology Shrinks

    Acute Care rose 22.5% year-over-year to $15.1 million on ZYNRELEF ($10.6 million, +13.8%) and APONVIE ($4.5 million, +49.3%); Oncology fell 22.2% to $20.1 million as CINVANTI dropped 16.6% and SUSTOL fell 92.0%.

  • Thin Cash Against Large Debt

    The company ended the quarter with $23.4 million in cash, cash equivalents and short-term investments, against $91.6 million of non-current notes payable and $34.4 million of convertible notes.

  • Loss Narrows, Adjusted EBITDA Positive

    Q3 net loss was $5.0 million versus $17.5 million a year ago; Adjusted EBITDA was $3.7 million versus $1.5 million.


Analysis · HRTX · Life Sciences

Q3 revenue fell 7.8% to $35.3 million as CINVANTI slid 16.6% and SUSTOL wound down, offset partly by 22.5% Acute Care growth. The company held just $23.4 million in cash against $126 million of notes payable, which is why the $145 million cash asset sale to CorMedix matters more than the quarter itself. Guidance remains withdrawn, and no conference call was held. The deal still needs a stockholder vote and customary closing conditions.

How filings like this one have moved

In the 30 days to Nov 9, 2026, 36.6% of the 2965 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, HRTX was trading at $0.38 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $55.6M. The 52-week trading range was $0.26 to $1.58. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

HRTX - Latest Insights

HRTX
Nov 09, 2026, 7:40 AM EST
Filing Type: 8-K
Importance Score:
10
Price at Filing: $0.3841
Real-time Price: $0.3663 info
Change: -$0.0178 (-5%) info
Market Cap: $55.627M info
HRTX
Aug 17, 2026, 7:27 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $0.3408
Real-time Price: $0.3663 info
Change: +$0.0255 (+7%) info
Market Cap: $55.627M info
HRTX
Aug 10, 2026, 8:00 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.4307
Real-time Price: $0.3663 info
Change: -$0.0644 (-15%) info
Market Cap: $55.627M info
HRTX
Aug 10, 2026, 8:00 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.4201
Real-time Price: $0.3663 info
Change: -$0.0538 (-13%) info
Market Cap: $55.627M info
HRTX
Jun 25, 2026, 5:00 PM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $0.410
Real-time Price: $0.3663 info
Change: -$0.0437 (-11%) info
Market Cap: $55.627M info